Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Acetaminophen · Ofirmev, NSC-109028

Small molecule · developed by Mallinckrodt Hosp

Approved FDA, Nov 2010
4 Registered trials

What is Acetaminophen?

Acetaminophen is a p-aminophenol derivative with analgesic and antipyretic activity. It is studied in thyroid and parathyroid conditions, glycogen storage disease type III, and acute and postoperative pain.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ofirmev, NSC-109028, NSC-3991, Active Comparator: HB/APAP, Antipyretic
Drug type
Small molecule
Pathways
nitric oxide pathway, prostaglandin synthesis
Therapy area
Metabolic, Oncology
Developer
Mallinckrodt Hosp
In trials of
LTGO, NERV, NVO, RARE
FDA status
Approved as Ofirmev (November 2, 2010), NDA022450
UNII
362O9ITL9D

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03469310 Phase 4 Thyroid Cancer Completed NERV
NCT07102459 Phase 2 Acute Pain Completed LTGO
NCT04990388 Phase 1/2 Glycogen Storage Disease Type III Terminated RARE
NCT07845578 Phase 1 Obesity Recruiting NVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute PainGlycogen Storage Disease Type IIIParathyroid AdenomaParathyroid DiseasesParathyroid HyperplasiaPostoperative Pain ControlThyroid CancerThyroid DiseasesThyroid GoitreThyroid NeoplasmsThyroid Nodule

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.